Peer-reviewed veterinary case report
Changes in blood proteins in dogs treated for leishmaniosis with two
By Daza González, M A et al.·Published in Veterinary journal (London, England : 1997)·2019·Hospital Clí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
- Species:
- dog
Plain-English summary
A group of dogs with leishmaniosis, a disease caused by parasites, were treated with either a combination of antimonial and allopurinol or miltefosine and allopurinol. Over three months, the dogs receiving the antimonial treatment showed a quicker improvement in certain blood proteins that indicate inflammation compared to those on miltefosine. Specifically, the antimonial group had a greater reduction in ferritin levels and an increase in a protective protein called PON-1. This suggests that the antimonial treatment may work better for managing leishmaniosis in dogs.
People also search for: dog leishmaniosis treatment · antimonial for dogs · miltefosine side effects in dogs
Abstract
The objective of this study was to compare changes in serum concentrations of acute phase proteins (APPs) and paraoxanase (PON-1) in response to two treatments in dogs with leishmaniosis (CanL). For this purpose, 20 dogs with CanL were assigned to two treatment groups: antimonial plus allopurinol (Group G, n=12) and miltefosine plus allopurinol (Group M, n=8). Serum concentrations of PON-1 and APPs including C-reactive protein, haptoglobin (Hp), ferritin (Ft) and albumin were monitored over a period of 3 months after treatment. At the beginning of the study (day 0), most of the dogs had APP abnormalities. None of the variables differed significantly between groups in the first or subsequent visits. There was a significantly higher reduction in serum Ft in Group G than in Group M from day 0 to day 30 (P=0.0085), and also from day 0 to day 90 (P=0.0214). There was a higher increase in serum PON-1 in Group G than in than Group M from day 0 to day 30 (P=0.0039), and also from day 0 to day 90 (P=0.0404). This is the first report of APPs in dogs with natural clinical leishmaniosis treated with miltefosine. There was faster resolution of serum APP concentrations in dogs treated with antimonials (P<0.05).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30819422/